SUMMARY The metabolism of pure radioiodine labelled Clq has been observed in five patients with ulcerative colitis, five patients with Crohn's disease, and in five control subjects. Both the fractional catabolic rate and the synthesis rate of Clq were increased in the five patients with Crohn's disease and in four of the five patients with ulcerative colitis. The fifth patient was in remission and had a normal synthesis rate. These results support the hypothesis that complement activation plays a role in the pathogenesis of these disease states and that the increased complement activation is primarily via the classical pathway.
Circulating immune complexes have been found in patients with active inflammatory bowel disease (Jewell and MacLennan, 1973; Doe et al., 1973; Mowbray et al., 1973; Ezer and Hayward, 1974) . They are frequently present in high titre in patients with extraintestinal manifestations (Hodgson et al., 1977a) and may be involved in their pathogenesis. Although the role of immune complexes in the pathogenesis of mucosal lesions is not clearly defined, an experimental immune complex mediated colitis can be produced in rabbits which is histologically similar to human ulcerative colitis (Hodgson et al., 1978) .
Hypercatabolism of the third component of complement, C3, has been demonstrated in patients with inflammatory bowel disease (Hodgson et al., 1977b) even though the serum concentrations are normal or raised (Ward and Eastwood, 1974; Hodgson et al., 1977c) . This component can, however, be activated either through the classical pathway by immune complexes, or the alternative pathway by substances such as bacterial endotoxins (Mergenhagen et al., 1973) . The aim of this study was therefore to investigate the catabolism of Clq, which is the subcomponent of the complement system that binds to immune complexes to activate the classical complement pathway. Received for publication 25 May 1979.
Methods

PATIENTS
The subjects studied comprised five patients with ulcerative colitis and five patients with Crohn's disease. Details of these patients are given in Table 1 . Diagnosis of ulcerative colitis and Crohn's disease was on the basis of clinical, radiological, and histological criteria. The severity of their disease was assessed according to the criteria of Truelove and Witts (1955) for ulcerative colitis and of de Dombal et al. (1974) for Crohn's disease. One patient with ulcerative colitis (E. McF) was in complete remission; five patients were on no treatment at the time of study and in the other five treatment was not altered immediately before or during the study. Five control subjects were also studied, four of whom were patients with non-inflammatory disorders (irritable colon syndrome, nutritional osteomalacia) and one healthy volunteer. The ages of the patients ranged from 24 to 70 years and that of the control subjects from 24 to 53 years. The Ethics Committee approved of the project and before each study began the informed consent and co-operation of the subject was obtained.
ISOLATION OF CIq
Pure, metabolically functional Clq was isolated from fresh human serum by the method of Reid et al. (1972) with minor modifications. The fresh human serum was obtained from a volunteer panel of donors at the Royal Free Hospital. The euglobulin fraction from 4 litres of serum was precipitated by dialysis against 0-02 M sodium acetate buffer, pH 5*5 Protein concentration was estimated using E 1c°n, 280nm =6-82 (Reid et al., 1972) . All buffers were prepared in 'water for injection' (Travenol Laboratories) and contained either streptomycin sulphate (100 mg/l) and benzyl penicillin (1 x 106 units/l) or gentamycin sulphate (80 mg/I) and the sodium salt of ampicillin (250 mg/I). All apparatus and buffers were either autoclaved or sterilised using commercial sterilising agents.
Protein purity was assessed by polyacrylamide gel electrophoresis, isoelectric focusing, analytical ultracentrifugation and its reaction to multispecific antisera (Hoechst). Biological activity was assessed by its incorporation into the Clq, r, s complex. Aliquots of plasma samples, obtained from subjects injected with 1251-Clq, were subjected to either gel filtration on a 90 cm x 8 cm2 Sepharose 6B column or sucrose density gradient ultracentrifugation on a 10-40% wt/wt phosphate buffered sucrose gradient. Gradients were prepared by the method of Britten and Roberts (1960) and centrifuged at 27 000 rev/min in a 3 x 25 ml swing-out rotor (MSE). In both cases fractions were tested for radioactivity and Cls activity against specific anti-Cls antiserum (Hoechst).
RADIOIODINE LABELLING OF Clq
Clq was labelled with 1251 by the method of McConahey and Dixon (1966) . Five to six milligrams of Clq in 3 ml 100 mM sodium phosphate buffer containing 1 mM EDTA, pH 7T0, was stirred in a beaker on an ice bath. To this was added 1 mCi of carrier free Na 1251 (Radiochemical Centre, Amersham) followed by 50 ,g chloramine-T in 0 5 ml pyrogen-free distilled water. After five minutes the reaction was stopped by the addition of 60 F±g sodium metabisulphite in 0-6 ml. The mixture was allowed to stand for an additional 10 minutes before being exhaustively dialysed, first against 100 mmol sodium phosphate buffer containing 1 mmol EDTA, pH 7-0 and then against 0-85% sodium chloride containing 1 mmol EDTA (tetrasodium salt), in order to remove unbound 1251. The 1251-Clq was then centrifuged at 85 000 g (ray) and 2°C for 1 hours to remove aggregates and any bacterial contamination.
One aliquot of each labelled batch was tested for pyrogens by injection into rabbits (Consultox Laboratories, Ealing). Batches were used only if they met the acceptable standards of negligible pyrogenicity and bacterial contamination as laid down in the European Pharmacopoeia (1971) .
EXPERIMENTAL PROCEDURE
Potassium iodide (30 mg twice daily) was administered to subjects 24 hours before the start of the study and then for seven days. After centrifugation to remove aggregates, weighed quantities of 1251-Clq were injected intravenously together with a weighed quantity of a solution of 1311 human serum albumin (Radiochemical Centre, Amersham). The total dose of radioactivity was less than 25 stCi.
Plasma samples were taken at five, 15, 30, and 60 minutes after injection, at two hours, four hours, eight hours, and thereafter twice daily for six days. The total volume of urine passed during the study was collected in 24 hour aliquots and, for the patients only, stool collections were also made. Two millilitre aliquots of the plasma and 5 ml aliquots of the urine were counted in an LKB 1280 ultragamma counter. The 1251 counts were corrected for crossover from the 1311 channel. The faeces were weighed, made up to a constant weight with water, and homogenised with a blender: 10 ml aliquots were counted. Two millilitre and 5 ml aliquots of standard solution of the injected proteins made up in 0-85 % saline containing Tween 80 were also counted.
Serum Clq concentrations were determined by a single radial immunodiffusion (Mancini et al., 1965) into 1 % phosphate buffered agarose, pH 7-2, containing anti-human Clq antiserum (Hoechst). Diffusion was allowed to go to completion (approximately 60 hours). Under these conditions it was found unnecessary to incorporate EDTA into the buffered agarose. Standards were prepared from purified freeze-dried Clq. Serum albumin concentrations were determined colorimetrically using bromocresol green (Doumas et al., 1971) . At least five separate determinations of the serum protein concentrations were made throughout each study. In no case did the serum concentrations vary significantly.
ANALYSIS OF DATA
The plasma of radioactivity disappearance curves were analysed by the multiexponential analysis technique of Matthews (1957) . Best fit curve stripping for two and three exponentials was achieved using a CDC 7600 computer (University College, London). The plasma volumes were estimated by extrapolating to zero time. Fractional catabolic rates (FCRs) were also determined using the integrated rate equations of Nosslin (1973) and the metabolic clearance of Berson and Yalow (1957) .
In the patient group, faecal counts were included in the calculation of metabolic clearance.
Results
The Table 3 and a typical example of U/P values is shown in Fig. 1 Fig. 2 and those for patients with Crohn's disease in Fig. 3 . In both the mean plasma disappearance curves for the control subjects ( ± 1 SD) is given for comparison. For the five patients with Crohn's disease there was an accelerated disappearance of the labelled protein from the plasma. This was also true of the four patients with active ulcerative colitis, but subject tBased on U/P data.
lated from these curves using multiexponential analysis are shown in Table 4 . Similar data for the catabolism of albumin are given in Table 5 . Although there is no significant difference in the serum Clq concentrations, the fractional catabolic rates and synthesis rates in nearly every case are markedly above those for the control subjects: the exception being the patient in remission at the time of the study (E. McF.). The accelerated catabolism cannot be accounted for by loss into the gastrointestinal tract. Table 6 shows the percentage of the injected dose lost over the first five days of the patient studies. In only one case (B.F.) did this exceed 3 %. The associated albumin data for these patients show no significant difference in albumin metabolism for the patients with ulcerative colitis compared with the control subjects, but a marked rise in those with Crohn's disease. (Waldmann, 1970) . It is also unlikely that we are merely recording a generalised increase in protein turnover, as in one group of patients (ulcerative colitis) raised Clq catabolism was seen with normal albumin turnover. In one patient, who was in remission, Clq metabolism was similar to the control subjects, which suggests that hypercatabolism occurs only in active disease. Obviously more patients in remission should be studied to confirm this, but it is difficult to admit well patients for metabolic studies when hospital admission is often a frequent event in the natural history of their disease.
The divergence between EV and IV distribution of Clq over the period of study in our patients is similar to that found by Kohler and MullerEberhard (1972) in patients with hypogammaglobulinaemia and in two patients with myeloma. Similar EV accumulation of C3 has been observed in patients with inflammatory bowel disease (Hodgson et al., 1977b) . These findings suggest retention of label within the EV compartment. This may occur as a result of increase in capillary permeability or of specific fixation of complement components at an EV site. In patients with inflammatory bowel disease it is possible that both mechanisms are operating within the inflamed mucosa.
Immunoglobulin production is greatly increased in the diseased intestine of these patients (McClelland et al., 1976) and some of this immunoglobulin has antibody specificity for bacterial antigens (Monteiro et al., 1971 
